Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in High Grade Neuroendocrine Neoplasms
NCT04412629Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2020
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in Neuroendocrine neoplasm (NEN), sponsored by Washington University School of Medicine. Primary endpoint: Objective Response Rate at 4 months. Started Nov 2020; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT04412629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412629.